Search research articles
Contact Us
Filters
Showing results (11-20 of 161) with videos related to
Page
of 17
Sort By:
The British Journal of Cardiology
|
June 24, 2022
Cancer immunotherapy and its potential cardiac complications
Simon G Findlay, Ruth Plummer, Chris Plummer
JCO Precision Oncology
|
June 12, 2024
Poly(ADP-Ribose) Polymerase Inhibitor Development: Promising Strategies to Move Beyond Approved Indications
Carlos Torrado, Ruth Plummer, Timothy A Yap
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 18, 2019
The DNA Damaging Revolution: PARP Inhibitors and Beyond
Timothy A Yap, Ruth Plummer, Nilofer S Azad, et al.
European Thyroid Journal
|
August 9, 2017
Tremelimumab-Induced Graves Hyperthyroidism
Earn H Gan, Anna L Mitchell, Ruth Plummer, et al.
Journal of Geriatric Oncology
|
February 9, 2019
Chronic cardiovascular toxicity in the older oncology patient population
Simon G Findlay, Jason H Gill, Ruth Plummer, et al.
Molecular Oncology
|
October 17, 2015
mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibition
Andrew J Massey, Peter Stephens, Rebecca Rawlinson, et al.
Future Oncology (London, England)
|
September 20, 2016
Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma
Kate Fife, Robert Herd, Susan Lalondrelle, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists
|
June 4, 2019
BRAF Wild-type, PTEN Mutant Malignant Uveal Melanoma Arising Within a Mature Ovarian Teratoma: A Case Report and Review of the Literature
Krisztina Lengyel, Fergus Young, Ali Kucukmetin, et al.
British Journal of Nursing (Mark Allen Publishing)
|
August 18, 2023
Impact of an educational intervention for advanced cancer patients referred for early phase clinical trials
Ben Hood, Ruth Plummer, Linda Hogarth, et al.
Cancer Chemotherapy and Pharmacology
|
June 2, 2014
Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors
Ruth Plummer, Peter Stephens, Louiza Aissat-Daudigny, et al.
Page
of 17
Search research articles
Search
Showing results (11-20 of 161) with videos related to
Sort By:
Page
of 17
The British Journal of Cardiology
|
June 24, 2022
Cancer immunotherapy and its potential cardiac complications
Simon G Findlay, Ruth Plummer, Chris Plummer
JCO Precision Oncology
|
June 12, 2024
Poly(ADP-Ribose) Polymerase Inhibitor Development: Promising Strategies to Move Beyond Approved Indications
Carlos Torrado, Ruth Plummer, Timothy A Yap
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 18, 2019
The DNA Damaging Revolution: PARP Inhibitors and Beyond
Timothy A Yap, Ruth Plummer, Nilofer S Azad, et al.
European Thyroid Journal
|
August 9, 2017
Tremelimumab-Induced Graves Hyperthyroidism
Earn H Gan, Anna L Mitchell, Ruth Plummer, et al.
Journal of Geriatric Oncology
|
February 9, 2019
Chronic cardiovascular toxicity in the older oncology patient population
Simon G Findlay, Jason H Gill, Ruth Plummer, et al.
Molecular Oncology
|
October 17, 2015
mTORC1 and DNA-PKcs as novel molecular determinants of sensitivity to Chk1 inhibition
Andrew J Massey, Peter Stephens, Rebecca Rawlinson, et al.
Future Oncology (London, England)
|
September 20, 2016
Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma
Kate Fife, Robert Herd, Susan Lalondrelle, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists
|
June 4, 2019
BRAF Wild-type, PTEN Mutant Malignant Uveal Melanoma Arising Within a Mature Ovarian Teratoma: A Case Report and Review of the Literature
Krisztina Lengyel, Fergus Young, Ali Kucukmetin, et al.
British Journal of Nursing (Mark Allen Publishing)
|
August 18, 2023
Impact of an educational intervention for advanced cancer patients referred for early phase clinical trials
Ben Hood, Ruth Plummer, Linda Hogarth, et al.
Cancer Chemotherapy and Pharmacology
|
June 2, 2014
Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors
Ruth Plummer, Peter Stephens, Louiza Aissat-Daudigny, et al.
Page
of 17